|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to explore the differential expression of miRNAs in patients with ITP before and after starting treatment with thrombopoietin-receptor agonists (TPO-RAs) to clarify their roles in the pathophysiology of ITP, and as potential diagnostic and prognostic markers of this disorder.
|
30885035 |
2020 |
|
Immune thrombocytopenic purpura
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
|
31146647 |
2020 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
|
31280643 |
2020 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
At this point, considering the limited treatment options due to toxicity and/or teratogenesis of other drugs proven to be effective against ITP like azathioprine, rituximab, cyclophosphamide, etc. and the risk of bleeding symptoms, either from mother or fetus, we decided to begin treatment with Romiplostim (thrombopoietin receptor agonist).
|
31116059 |
2020 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Romiplostim (Nplate<sup>®</sup>), a thrombopoietin receptor agonist, is the first FDA-approved thrombopoiesis-stimulating protein for the treatment of low platelet (PLT) counts in adults with chronic immune thrombocytopenia.
|
31021662 |
2020 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists.
|
31805421 |
2020 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Eltrombopag (ELT) is a thrombopoietin receptor activator that has shown efficacy in chronic immune thrombocytopenia.
|
31205222 |
2020 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the last years, the use of thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, has improved the management of immune thrombocytopenia (ITP).
|
31838946 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The introduction of thrombopoietin receptor agonists (TPO-RAs), which increase platelet production, dramatically changed the treatment landscape for ITP by providing patients with well-tolerated, long-term treatment options.
|
31156798 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
|
30854783 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Romiplostim is a thrombopoietin receptor agonist recommended as a second-line therapy for immune thrombocytopenia.
|
29298625 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
The thrombopoietin receptor agonist romiplostim is approved for second-line use in chronic immune thrombocytopenia (ITP), but its effects in patients with ITP for ≤1 year are not well characterized.
|
30793285 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then, their use has progressively increased around the world; they are currently used in more than 100 countries.
|
31073079 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thrombopoietin-receptor agonists (TPO-RAs) are the only American Society of Hematology (ASH) guideline-advocated, second-line treatment for immune thrombocytopenia (ITP) that have been validated by randomized, controlled trials with a placebo comparator.
|
30799645 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
|
30880797 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis.
|
30810479 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
The thrombopoietin receptor agonist romiplostim is used for the long-term treatment of chronic immune thrombocytopenia (ITP).
|
30446804 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment.
|
29293383 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
|
31723222 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
: Thrombopoietin receptor agonists (TPO-RA) are currently approved to treat chronic immune thrombocytopenia (ITP) but there is increasing interest in considering these drugs earlier during the course of the disease.
|
31259778 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations.
|
31818701 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thrombopoietin receptor (TPO-R) agonist, which is responsible for increasing platelet count, is a novel treatment option for chronic ITP patients.
|
31192066 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A proportion of patients with immune thrombocytopenic purpura are refractory to multiple therapies including thrombopoietin-receptor agonists (TPO-RA).
|
30972617 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subsequent treatment of adult ITP is typically with thrombopoietin receptor agonists (TPO-RAs; romiplostim or eltrombopag), rituximab, or splenectomy.
|
31830764 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.
|
31007886 |
2019 |